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Objective: To estimate differences in treatment costs and health outcomes between 
non-myeloablative hematopoietic stem cell transplantation (HSCT) and disease-
modifying therapies (DMTs) for the treatment of relapsing-remitting multiple 
sclerosis (RRMS). 
 
Methods: We collected data on costs and charges for patients who underwent HSCT 
for RRMS at Northwestern Memorial Hospital in Chicago (USA) between January 
2017 and January 2019. The costs of HSCT were compared against those for DMTs in 
the United States, obtained from the literature. We also conducted a literature review 
to interpret the cost comparisons in terms of disease control and patients’ wellbeing 
defined as no evidence of disease activity (NEDA), neurologic disability by the 
expanded disability status scale (EDSS), and quality of life by the short form SF-36, 
respectively.  
 
Results: Outside of the data, herein, no other studies on cost of HSCT for RRMS were 
found in the literature. HSCT mean total costs, based on our own hospital, were 
$85,184 (range ($70,635 to $120,260). Mean revenue collected was $95,268 (range 
$16,544 to $173,204). In comparison, according to the literature, 2019 DMT costs in 
the USA ranged from $80,000 to $100,000 per year per patient.  Compared to DMTs, 
studies of HSCT reported greater improvement in no evidence of disease activity, 
disability, and quality of life. 
 
Limitations: Costs of HSCT would be expected to vary by conditioning regimen 
utilized, patient selection, center experience, and regional variation. No cost data on 
other HSCT regimens or on the three most recent DMTs, alemtuzumab, ocrelizumab 
and ocrelizumab, are available. Randomized trials for cost comparisons are missing 
and variations in HSCT designs, populations, and methodology preclude more precise 
cost estimates. 
 
Conclusion: Costs of non-myeloablative HSCT after which DMTs are indefinitely 
discontinued, are approximately the same as those for one year of prescription DMTs. 
Since DMTs assessed in this analysis are given on an ongoing basis, whilst HSCT is 
not, HSCT is expected to produce long-term cost-savings. When considered alongside 
the available clinical evidence, which suggests that HSCT may generate more health 
gains than DMTs, HSCT is likely to represent a cost-effective use of resources. Model-










Multiple sclerosis (MS) is a central nervous system demyelinating disease that has 
been reported to affect from 400,000 to 727,000 people in the United States (US) (1-
3). It is a chronic disease with peak onset at the age of 30 years old but may present 
later in life or, less commonly, in teenage or childhood years (4,5).  MS is second only 
to congestive heart failure in terms of the costs of care for a chronic illness (6).  
 
Lifetime direct costs per patients are greater than $ 4 million US dollars (7), the 
majority of which are attributable to prescription drugs, i.e. disease-modifying 
therapies (DMTs). In the US, DMT prices have increased five to seven times faster than 
the rate of inflation (8-10). In the 1990s, interferons (first-generation DMTs) cost 
$8,000 to $11,000 per year (8). In 2004, the average yearly DMT costs per person 
were $26,050 (9). In 2013, average yearly DMT costs rose to $60,000 (8). In 2017, 
costs for most DMTs exceeded $70,000 per year (10), and by 2019, DMT costs were 
between $80,000 to $100,000 per year per patient (11). Despite having been available 
for a long time, and their comparatively lower efficacy, charges for older first-
generation DMTs have continued to increase at a pace that is consistent with the 
newer second- and third-generation DMTs (10, 11). DMTs are expensive, and while a 
few such as alemtuzumab or cladribine are taken as pulses over 2 years, most DMTs 
have to be taken on a continuous, chronic, and life-long basis, resulting in the accumulation of substantial healthcare costs over the patient’s lifetime as well as 
excessive out-of-pocket costs and onerous pharmacy benefit restrictions which can 
all negatively affect adherence to medications and medical advice.   
 
Autologous hematopoietic stem cell transplantation (HSCT) is a therapeutic 
intervention in which chemotherapy and mono or polyclonal antibodies (the 
conditioning regimen) are given over several days, followed by the infusion of 
hematopoietic stem cells (HSCs) to hasten recovery of lympho-hematopoiesis. 
Autologous HSCT for RRMS is an immune-based therapy based on the concept that 
the conditioning regimen will cytoreduce disease-causing lymphocytes and stop 
inflammation (stop co-stimulation), while rapid immune regeneration without 
inflammation will reintroduce tolerance to self-epitopes via a rebound in regulatory 
and suppressor T cells. A normalization of pro-inflammatory gene expression profile 
and normalization of pro-inflammatory lymphocyte subsets ensues after HSCT (12-
14). After an autologous non-myeloablative HSCT, hematopoietic and immune 
recovery will occur spontaneously, but autologous HSCs (collected before the 
conditioning regimen was given) are reinfused as an autologous supportive blood 
product to accelerate hematopoietic recovery. 
 
HSCT is given as a once-only procedure, including a 14 to 15 day hospital stay. After 
discharge, outpatient blood work is checked weekly for 4 weeks and then every two 
weeks for 2 months, and while all DMTs and immune-based drugs are discontinued, 
oral antibiotics such as fluconazole and co-trimoxazole are taken orally for 3 months 
and acyclovir for one year. However, the vast majority of these costs are accrued 
within the 14 to 15 days required for hospitalization, with very few costs being 
incurred thereafter.  




In this paper, we provide a preliminary comparison of the costs and outcomes in 
terms of no evidence of disease activity (NEDA) (15), improvement in neurologic 
disability i.e. decrease in Expanded Disability Status Scale (EDSS) (16), and changes 
in physical component summary, mental component summary, and total score of the 
quality of life short form 36 (SF-36) associated with non-myeloablative HSCT, 
compared with those for DMTs. First generation DMTs i.e. copaxone or interferons 
have a 2-year NEDA of approximately 30% (44) while second or third line DMTs have 
a 2-year NEDA up to 50% (44). An improvement in neurologic disability (defined as 
a decrease in the EDSS by 0.5 to 1.0) (17) or a minimal clinical meaningful 
improvement in the SF-36 by 5 points (18) has not, to our knowledge, been achieved 
by DMTs in any study cohort. The aim, herein, is to inform judgments and stimulate 






Setting and design 
Enrolment in the MIST randomized trial of HSCT versus DMTs for RRMS was 
completed in 2016 and the results were published in January 2019 (30). As the costs 
of HSCT were not captured in that study, we elected to assess the costs of HSCT 
using the same treatment regimen utilized in MIST for patient with RRMS that were 
treated at the same center using the same eligibility, conditioning regimen, and 
same standard of care guidelines between January 2017 and January 2019. 
 
Patient selection 
Patients were offered autologous non-myeloablative HSCT if they fulfilled the MIST 
inclusion and exclusion criteria (30). In brief, patients were 18 to 55 years old, had an 
established diagnosis of RRMS based on the McDonald’s 2010 diagnostic criteria (46) 
with two acute relapses, or one relapse with MRI evidence of disease activity at a 
separate time point, within the last year despite the use of DMT and an EDSS of 
between 2.0 and 6.5. Patients were excluded for primary or secondary progressive 
multiple sclerosis; hereditary neurologic diseases; pregnancy; pulmonary, cardiac, 
renal, or liver dysfunction; abnormal platelet or white blood cell counts; active 
infection; prior treatment with alemtuzumab or mitoxantrone; or use of natalizumab 
within the prior 6 months, fingolimod within 3 months, or teriflunomide within 24 
months (unless they underwent successful accelerated elimination procedure).  
 
Hematopoietic stem cell collection and transplantation procedure 
All patients were treated per the MIST protocol. Peripheral blood stem cells (PBSC) 
were collected as an outpatient 10 days after a 23-hour admission for intravenous 
cyclophosphamide (2 g/m2). Outpatient subcutaneous filgrastim was given starting 5 
days after cyclophosphamide at 5 to 10 μg/kg per day until day 10. Two weeks later 
patients were admitted to the hospital for the conditioning regimen consisting of 
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intravenous cyclophosphamide 50 mg/kg per day on days –5 to day -2 before stem 
cell transplantation and rabbit anti-thymocyte globulin, 0.5 mg/kg on day -5, 1.0 
mg/kg on day -4, and 1.5 mg/kg on days -3, -2 and -1. Methylprednisolone (1000 mg) 
was infused 30 min prior to rabbit anti-thymocyte globulin infusion. Beginning on day 
0, daily oral prednisone was dosed at 60 mg for 3 days, 40 mg for 2 days, 20 mg for 2 
days, and 10 mg for 2 days. Filgrastim (5–10 μg/kg per day) was started on day +4 
and continued until engraftment. 
Hydration (125–150 mL normal saline per hour), diuretics, and intravenous mesna 
were continued until 24 h after the last dose of cyclophosphamide. A Foley catheter 
was placed in patients with greater than 60 mL of postvoid urinary residual. 
Intravenous cephalosporin was started on day 0. Intravenous vancomycin was added 
for a febrile episode. Methylprednisolone (250 mg) was infused for rabbit anti-
thymocyte globulin–related fever. Patients remained hospitalized until recovery of 
peripheral blood counts which occurred a mean of nine days after hematopoietic 
stem cell infusion for a total hospital stay of 14 days. 
Oral acyclovir was started on admission and continued for 1 year. Oral fluconazole 
was started on day +2, and oral trimethoprim-sulfamethoxazole or monthly 
nebulized pentamidine was started after platelet engraftment and continued for 3 
months. Cytomegalovirus viral load was monitored for 90 days and was treated 
preemptively by switching from acyclovir to oral valganciclovir (900 mg twice daily) 
until testing negative by quantitative polymerase chain reaction.  
Hematopoietic stem cell costs 
Costs for HSCT incorporated outpatient pre-transplant work-up and mobilization and 
harvesting of PBSCs. These costs included blood draws, magnetic resonance imaging 
(MRI), echocardiograms, electrocardiograms, chest radiograph, and PBSC 
leukapheresis and cryopreservation. Charges for inpatient transplantation included 
the conditioning regimen drugs (cyclophosphamide and ATG), PBSC reinfusion, all 
pharmaceutical medications including antibiotics and anti-emetics, intravenous 
fluids, nursing care, blood draws, laboratory tests, blood transfusions including 
packed red blood cell and platelets, and room charges until the time of hematopoietic 
recovery and discharge. The only direct costs not captured because they were under 
a different revenue stream were those related to physician initial outpatient 
assessments and daily inpatient follow ups.  
 
Analysis of HSCT costs was separated into direct costs related to patient care (e.g. 
medications, laboratory tests, imaging studies, transfusions, nursing care), and 
overhead costs which are necessary to operate a hospital but not directly related to 
inpatient care (e.g. management, supervision, medical records, accounting, 
information systems, marketing, legal, malpractice insurance, building maintenance 
and depreciation, house-keeping). The costs were the sum of direct and overhead 
costs. And the total net income is net revenue collected. 
DMT costs  
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In order to provide a basis for comparing the costs of HSCT and DMT, we conducted 
a simple PubMed search for all published papers using the term “multiple sclerosis healthcare costs” and the subject headings of HSCT and DMT for the same time 
interval of January 2017 to January 2019. 
 
Outcomes for HSCT versus DMTs in RRMS 
In order to provide a basis for understanding the implications of the differences in 
outcomes between alternative treatment approaches, we undertook an additional 
search in PubMed to identify studies reporting on clinically relevant outcomes for 
HSCT and/or DMTs in RRMS populations. The search was limited to studies published 
in the English language between 2010 and January 2020 and included the terms “multiple sclerosis disease modifying therapy” or “multiple sclerosis hematopoietic stem cell transplantation” and the subject headings of “no evidence of disease (NEDA) 
(12), quality of life SF-36, or EDSS scale (13)”. The purpose of this search was not to 
systematically identify and review all available evidence, but rather to provide an 
overview of the comparative effectiveness of HSCT and DMTs in terms of clinical 
outcomes and quality of life (QoL).  
 
To identify DMT studies, we used pivotal phase 3 clinical trials for each approved 
DMT: ADVANCE (pegylated interferon beta-1a) , AFFIRM (natalizumab), CARE-MS I 
(alemtuzumab), CARE-MS II (alemtuzumab), CLARITY (cladribine), CLIMB (standard 
of care), CombiRx (combined interferon beta-1 alpha and glatiramer acetate), 
CONFIRM (dimethyl fumarate), DEFINE (dimethyl fumarate), FREEDOMS 
(fingolimod), FREEDOMS II (fingolimod), OPERA I and II (ocrelizumab), SENTINEL 
(natalizumab), TEMSO (teriflunomide), TOWER (teriflunomide), and TRANSFORMS 
(fingolimod). FDA approved drugs that have been removed from market, e.g. 
daclizumab, or are no longer commonly prescribed, e.g. mitoxantrone, were excluded.  
 
Health outcomes were operationalized in our synthesis using three commonly 
measured outcomes of disease activity and disability: no evidence of disease activity 
(NEDA) (15), expanded disability status scale (EDSS) (16), and quality of life short 
form 36 (SF-36).  NEDA is defined as no relapses, no progression, and no new or 
enhancing lesions on magnetic resonance imaging (15). The mean change in EDSS 
score was used to evaluate neurologic disability (16). Analysis of EDSS was limited to 
studies that reported EDSS change for the entire study group.  The numerical EDSS 
disability score ranges from 0 (no neurologic disability) to 10 (death due to MS) in 
0.5-point increments (17). Neurologic improvement is usually defined as a decrease 
of EDSS by 1.5, 1.0, or 0.5 points for an enrollment EDSS of < 2.0, 2.0 to 5.5, or  6.0, 
respectively (17). Similarly, quality of life was limited to studies reporting the SF-36 
QOL questionnaire that is composed of a physical component summary (PCS), a 
mental component summary (MCS) and total scores (TS). To achieve a minimal 
clinically meaningful difference in QOL scores requires a change of 5 points (18). 
When multiple studies were available, we limited results to the initial study or the 
first post-hoc analysis. We excluded studies of secondary progressive or primary 
progressive MS. 
Statistical analysis 
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DMT costs obtained from the literature were informative analysis of mean or median 
costs per drug which was not based on direct comparison of DMT treatment arms in 
randomized trials. Similarly, we calculated the mean, median, range, standard 
deviation (SD) of HSCT cost in our cohort. Outcome measures of NEDA, EDSS, and SF-
36 published in the literature on DMT and HSCT were summarized in order to 




Costs of non-myeloablative HSCT versus DMTs for RRMS 
Cost analysis was available on 37 patients. The cohort had a mean age of 38 years, 
(range 26 - 51), with a female to male ratio of 2.7, and a mean EDSS score of 3.7 
(median of 3.5, and range of 2 to 6.5). All had previously received DMTs including 
interferon-beta-1a=25/37 (66%), interferon beta 1b = 7/37 (19%), glatiramer 
acetate = 24/37 (65%), natalizumab = 16/37 (43%), dimethyl fumarate = 20/37 
(54%), fingolimod = 9/37 (24%), teriflunomide = 6 / 37 (16%), ocrelizumab = 3/37 
(8%), cladribine = 1/37 (2.7%). They also received other immune suppressants 
including corticosteroids = 37/37 (100%), rituximab=1 /37 (2.7%), intravenous 
immunoglobulin (IVIG)=2/37 (5%), mycophenolate mofetil = 1/37 (2.7%), 
mesenchymal stem cells = 1/37 (2.7%), hydroxychloroquine = 2/37 (5%), and 
leflunomide = 1/37 (2.7%). 
 
Our search identified three publications that documented annual DMT costs (10, 11. 
19), of which only one study reported costs of DMTs for patients with RRMS during 
the same time period as HSCT data were collected, i.e. from 2017 to 2019 (11). This 
study reports that the mean drug acquisition costs for DMTs in the US are more than 
$86,000 per patient per year. This estimate excludes all other costs associated with 
the management of the disease, for example, physician visits, other medications, 
imaging, and management of relapses; hence, the true costs of treating RRMS patients 
on DMTs will be higher. Given previous trends in increasing prices of DMTs, it is 
reasonable to expect that these costs will continue to rise in the future 
 
Comparison of health outcomes for non-myeloablative HSCT versus DMTs in patients 
with RRMS 
Figure 2 presents a comparison of change in EDSS scores reported within the HSCT 
and DMT studies identified by the search. With the exception of natalizumab (20,21) 
and alemtuzumab (22,23), no DMT trial have reported improvement in EDSS on the 
entire study cohort in their per protocol analysis. The alemtuzumab CARE-MS I study 
reported a decrease (improvement) in EDSS of 0.13 and 0.14 at 1 and 2 years (22), 
while the alemtuzumab CARE-MS II study reported a decrease in EDSS of 0.14 and 
0.17 at 1 and 2 years (23). The Tysabri (natalizumab) Observational Program (TOP) 
reported an EDSS score decrease of 0.2 at 1, 2, 3, and 4 years (24).  HSCT trials for 
RRMS reporting EDSS for the study cohorts have demonstrated decreases 
(improvements) of > 0.5 point or more (Figure 2) (25-30).  
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Figure 3 presents a summary of NEDA outcomes reported within the identified HSCT 
and DMT studies. For peginterferon beta-1a (ADVANCE study), NEDA was 34% at one 
year (31). In the AFFIRM trial of natalizumab, NEDA was 47% and 37% at one and 
two years, respectively (32). For alemtuzumab (CARE-MS I study), NEDA was 39% at 
two-years (22).  The CLARITY oral cladribine study had a two-year NEDA of between 
44 and 46% with a placebo of 16% (33). The CombiRx study demonstrated that the 
combination of interferon and glatiramer acetate provided a three-year NEDA of 33% 
versus 21% for interferon alone and 19% for glatiramer acetate alone (34). When 
NEDA was evaluated in clinical practice independent of a specific DMT, the Harvard 
Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) study had a 
NEDA of only 15% at 5 years and 7.9% at 7 years (35). When data from the DEFINE 
and CONFIRM studies were combined, the two-year NEDA for dimethyl fumarate 
versus placebo was 26% and 12%, respectively (36). For Fingolimod (FREEDOMS 
study) the reported NEDA at two-year is 33% versus 13% for placebo (37). The 
TRANSFORMS study of fingolimod reported a one-year NEDA of 38% (38). For 
combined OPREA I and II trials, ocrelizumab achieved a two-year NEDA of 47% (39). 
In summary, for first generation DMT (interferon and glatiramer acetate) NEDA is 
approximately 30% to 35% at two years, while second and third generation DMTs 
have reported a NEDA of approximately 40% to 50% at 2 years. In contrast, after 
HSCT for RRMS, NEDA is roughly 70% to 90% at 2 years and 60% to 80% at 5 years 
(25-30).  
 
Figure 4 summarizes SF-36 outcomes reported within the HSCT and DMT studies. 
Most DMT trials report only the SF-36 physical component summary (PSC) while 
omitting mental component summary (MCS) or total scores (TS). PCS improved by 
0.33 points with use of ocrelizumab (40), by 1.03 points with natalizumab (41), and 
by 2.4 points with alemtuzumab at 2 years (42). In comparison, the SF-36 QOL after 
HSCT with the same non-myeloablative regimen of cyclophosphamide and ATG led to 
a clinically meaningful increase of 16 to 22 points at 2 years (25-30). 
 
Discussion 
Although the data related to the costs of DMTs and clinical and MRI outcomes for both 
DMTs and HSCT for RRMS have been obtained from the published literature, we 
present herein the first report to our knowledge on the costs and reimbursements of 
HSCT for RRMS and comparison of durability of important outcomes of NEDA, 
improvement in neurologic disability (i.e. EDSS), and quality of life after treatment 
with either DMTs or HSCT. Based on our own data from Northwestern using the MIST 
conditioning regimen, the mean direct costs of HSCT were $42,295 (range $33,887 to 
$57,704) and mean overhead costs were $42,888 (range $33,653 to $62,555). The 
mean charges for HSCT are $98,000. This one-time cost of HSCT compares favorably 
with the historical one-year costs of outpatient pharmaceutical drugs (DMT) that are 
reported to be between $80,000 and $100,000 per year (11) We separated costs into 
direct patient care costs and overhead institutional costs, because the costs for doing 
a non-myeloablative HSCT for RRMS in public health systems such as the UK's 
National Health System (NHS) is approximately 30,000 – 35,000 pounds (full analysis 
pending) which at first glance appears to be half of the cost of HSCT in the USA. 
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However, in public health systems the overhead costs are not counted inpatient costs, 
whereas in the American private health care system both overhead and direct costs 
are counted because both must be recovered from the patient's private health 
insurance. 
 
The true costs of DMTs are impossible to ascertain because of the commercial 
sensitivities and variability in insurance reimbursement, but the annual average DMT 
cost for an uninsured patient in the USA is $86,000 per year. Assuming approximately 
85% of HSCT-treated patients will remain relapse-free and drug-free for 5-years, a 
conservative estimate for the net savings in drug charges will be approximately 
$292,400 per HSCT-treated patient over this period ($86,000 x 0.85 x 4 years). This 
cost saving is likely to represent an underestimate, as it assumes that DMT prices will 
remain stable over time; given previous trends in inflating prices for DMTs, in reality, 
it is more likely that these will continue to increase well above the rate of inflation. In 
contrast, HSCT regimens employ generic patent-expired drugs whose costs are 
unlikely to increase faster than inflation.  
 
We did not include indirect costs of loss of work productivity that would likely favor 
HSCT. In the USA, loss of employment results in loss of insurance. Since, for most 
people, DMT prices are unaffordable as an out-of-pocket expense, the result will be 
untreated disease with acceleration of disease activity and progression. In 
comparison, after HSCT, all DMT drugs are normally discontinued and loss of 
insurance due to unemployment will not increase out-of-pocket disease-related 
financial burden or risk of disease progression for patients that remain in long-term 
drug-free remission. Since compared to 1st and 2nd generation DMT, the 3rd generation 
higher efficacy DMT drug natalizumab has been reported to improve work efficiency 
and attendance (43), HSCT which provides a meaningful improvement in QOL (44), 
may translate into a more pronounced impact on work productivity. Over the longer-
term, it is reasonable to expect that compared with DMTs, HSCT may both improve 
patient health whilst also accumulating substantial cost-savings which may be far 
greater than the estimate presented here. 
 
Comparisons of published data on change in NEDA, EDSS, and SF-36 indicate that 
HSCT is a highly effective therapy in well-selected patients with RRMS. Each of these 
three instruments capture a different aspect of treatment outcome. NEDA captures 
no evidence of new disease, i.e. stable disability; EDSS captures improvement in 
neurologic disability, i.e. reversal of disability; while SF-36 captures the physical and 
mental components associated with improvement in quality of life. Currently, the 
most effective DMTs report NEDA of approximately 50% at 2-year while HSCT 
reports a NEDA of 80–90% during the same time interval. DMTs do not improve 
(decrease) EDSS scores in patients with RRMS with the exception of alemtuzumab 
and natalizumab (Fig. 2) which decrease EDSS scores by 0.2 point, less than what is 
needed to be clinically significant (i.e. 0.5 point). In comparison, HSCT for RRMS 
results in a clinically significant improvement (decrease) in EDSS by 0.7 to 2.5 points 
(Fig. 2). In the MIST trial, HSCT improved mean EDSS scores by 1.0 point while the 
mean EDSS scores worsened (increased) by 1.0 point in the DMT arm (30). Although 
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the improvement in EDSS scores after HSCT may be due to “regression to the mean”, 
such an improvement was not observed in the DMT arm of the randomized MIST trial. 
In fact, EDSS scores in MIST DMT arm worsened (increased) during the trial period, 
and no previous DMT study has achieved a sustained regression to the mean that was 
clinically meaningful (a decrease of 0.5 points or more) as demonstrated in the 
various HSCT studies. 
 
The study presented herein is subject to several limitations. Firstly, the cost estimates 
for HSCT were obtained from a single center; costs for HSCT would be expected to 
vary by conditioning regimen utilized, patient selection, center experience, and 
regional variation. Costs could vary significantly between different conditioning 
regimens for example the term HDIT (high dose immune therapy) is an acronym used 
for myeloablative regimens that some centers are utilizing for multiple sclerosis (28). 
Herein and in our prior publications, we utilize an immune specific non-
myeloablative regimen. A second limitation is that retrospective comparison between 
different studies which have their own settings and patient populations is difficult. 
Undertaking robust cost-effectiveness analyses of treatment modalities whether 
between different DMTs or between DMTs versus HSCT requires a head to 
head comparison in a randomized trial. As this is the first manuscript on health 
economics of HSCT for RRMS, we hope that this publication will stimulate the interest 
of physicians and providers, whether private insurance or governmental, to look 
further into this subject. We also caution that costs will depend on the HSCT regimen 
used which in this analysis was based on a less expensive non-myeloablative regimen. 
While patients stop and remain off DMTs after HSCT and no immune based therapy 
is given after hospital discharge, other post-transplant 100 day costs of monitoring 
blood draws were not captured.  We also are not able to factor in offsetting costs of 
proprietary outpatient pharmaceutical rebates which can reduce net DMT costs (45).  
National variations in HSCT treatment regimens and patient populations preclude 
more precise cost estimates.  
 
Summary 
It is not just cost of a treatment but also its clinical efficacy that is important in terms 
of optimal health care. Data collated from the published literature and summarized 
herein suggests that HSCT may be a ‘win-win’ in terms of both cost and clinical 
efficacy. On the basis of the information presented here, it is reasonable to expect that 
HSCT may generate cost-savings and additional health gains for well-selected RRMS 
patients, compared with standard DMTs, although properly designed randomized 
trials will be needed. Formal model-based health economic analyses are required to 
substantiate this conclusion. 
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Table 1: Comparison of financial outlay of non-myeloablative HSCT 
versus DMTs 
Parameter Mean / median (range) (Standard 
deviation, SD) in US dollars 
Non-myeloablative HSCT 
HSCT direct costs $ 42,295 / $41,432 ($33,887- 
$57,704) (SD= $5,361) 
HSCT overhead costs $ 42,888 / $41,456 ($33,653 - 
$62,555) (SD = $6,533) 
HSCT total costs $ 85,184 / $83,480 ($70,635 - 
$120,260) (SD=$10,336) 
HSCT reimbursement (net 
revenue) 
$ 95,268 / $101,141 ($16,544 - 
$173,204) (SD = $39,239) 
DMT 
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Figure 1: Cost in US dollars for non-myeloablative HSCT in 37 patients with 
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Figure 2: Improvement in neurologic disability  after HSCT versus DMT 
 
CARE MS = Comparison of Alemtuzumab and Rebif Efficacy Multiple sclerosis, CARE 
MS 1 (ref 22), CARE MS 2 (ref 23), TOP= TYSABRI Observational Program (ref 24), 
DMT = disease modifying therapy i.e. prescription drug therapy e.g. Alemtuzumab or 
Natalizumab (Tysabri), EDSS=expanded disability status scale (lower number is 
improvement in neurologic disability), HSCT = hematopoietic stem cell 
transplantation. HSCT = hematopoietic stem cell transplantation studies i.e. Multiple 
sclerosis international transplant (MIST) (ref 30), Chicago study (ref 25), Sweden  
study (ref 26,29), High-Dose Immunosuppression and Autologous Transplantation 
Multiple sclerosis  (HALT-MS) study (ref 28)  
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Chicago=single center HSCT trial (ref 25), DMT = Disease modify therapy, i.e. 
prescription drugs HSCT = hematopoietic stem cell transplantation studies. HALT-
MS=High-Dose Immunosuppression and Autologous Transplantation Multiple 
sclerosis (ref 28), MIST = Multiple sclerosis international transplant (ref 30), NEDA = 
no evidence of disease activity, i.e. no relapses, no progression, no new or enlarging 
or enhancing lesions on magnetic resonance imaging, Sweden= single country HSCT 
trial (ref 29).  
 
NEDA for the following DMT trials: ADVANCE trial (peginterferon beta-1a) 34% at 1 
year (ref 31); AFFIRM (natalizumab) 47% and 37% at 1 and 2 years, respectively (ref 
32); CARE MS I (alemtuzumab) 39% at 2 years (ref 22); CLARITY (cladribine) 44% at 
2 years (ref 33); CombiRx (interferon plus glatiramer acetate) 33% at 3 years (ref 
34);  CLIMB (standard of care) 15% at 5 years (ref 35), CONFIRM and DEFINE 
(dimethyl fumarate) 26% at 2 years (ref 36); FREEDOMS (fingolimod) 33% at 2 years 
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AFFIRM and SENTINEL (natalizumab) trials (ref 41), CARE MS I and II (alemtuzumab) 
trials (ref 42).  Chicago HSCT trial (ref 25), HSCT=hematopoietic stem cell 
transplantation. MCS = mental component summary of SF-36, MIST = Multiple 
sclerosis International Stem cell Transplant trial (ref 30), OPERA I and II 
(ocrelizumab) trials (ref 40), PCS=physical component summary, TS = total score.  
 
